Articles tagged with Drug Therapy
A new clinical trial at IU School of Medicine shows that Burosumab significantly alleviates symptoms of X-linked hypophosphatemia, a phosphate-wasting disease causing rickets and osteomalacia. The study found substantial healing in 72% of children treated with Burosumab versus 6% in the conventional therapy group.
The Obesity Medicine Association announces major updates to its adult obesity algorithm, addressing key health consequences and treatment strategies. The new guidelines provide comprehensive guidance for healthcare professionals on managing the chronic disease of obesity, including nutrition, physical activity, and pharmacotherapy.
A new computational framework has compared four rheumatoid arthritis medications' impact on biological pathways in mice, revealing previously unknown differences in gene expression. The study suggests that some treatments may affect non-arthritis-related genes, providing new insights into arthritis pathology mechanisms.
Researchers at Karolinska Institutet have identified blood-based biomarkers that can determine which patients with advanced prostate cancer will benefit from continued hormonal therapy. The study suggests that patients with a normal TP53 gene and fewer AR resistance markers may benefit more from treatment.
Researchers compare substance users and non-users with eating disorders to identify key differences. Teens with eating disorders who used substances were more likely to have bulimia nervosa or anorexia nervosa binge/purge subtype, but also had similar physical health characteristics as non-users.
A 12-year retrospective clinical study shows the long-term effectiveness of PRRT, allowing patients to maintain a high quality of life. The overall response rate is about 70-80 percent, and prognosis is generally favorable for patients who respond to therapy.
GlycoNet researchers Drs. Alexey V. Pshezhetsky and Christopher Cairo have been awarded half a million dollars to advance research on human neuraminidase inhibitors for treating cardiovascular and autoimmune diseases. The funding will support the development of novel treatments for these complex diseases.
New study finds a modest increase in depression treatment rates, but non-financial barriers persist. Medicaid expenditures for mental health conditions have increased significantly, while uninsured individuals experience a decrease in care.
A study found that a spinal muscular atrophy drug can improve motor function and stabilize disease activity in older children with the disease, even those with SMA type II and III. The treatment, nusinersen, increased protein production essential for motor neurons to survive.
A study published in Annals of Internal Medicine found that metformin helped patients maintain weight loss over a period of 15 years. The researchers identified being older and losing a greater amount of weight in the first year as key predictors of lasting weight loss.
DNDi and Atomwise collaborate to develop first-in-class treatments for Chagas disease using AI, delivering drug-like compounds that will undergo further optimization and potential drug development. The research aims to address a public health challenge affecting millions worldwide.
A nationwide survey found that 33.3% of cancer patients used complementary and alternative medicines, with herbal supplements being the most common. Many participants did not disclose their CAM use due to lack of physician inquiry or perceived unnecessary information.
A USC study found that despite substantial media attention, most cancer drugs in shortage had little to no effect on chemotherapy treatment. Researchers analyzed over 2.4 million claims and found minimal change in treatment for the majority of oncology drugs during shortages.
A recent study found that nearly 18% of multiple sclerosis patients were misdiagnosed before receiving treatment at two major Los Angeles medical centers. The study revealed that many patients spent an average of four years being treated for MS before receiving a correct diagnosis.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
Researchers at UTMB are developing rapid-acting vaccines and broad-spectrum treatments for Ebola and Marburg, two highly-lethal hemorrhagic fever viruses considered Tier 1 pathogens. The $35M NIH grant will support the creation of new vaccines and treatments to address high mortality rates ranging from 50-90%.
Researchers at Osaka University have developed a therapeutic drug that emits highly effective alpha rays to treat refractory thyroid cancer. The study showed promising results, with mice surviving nearly three times longer and tumors shrinking by several-fold after treatment.
Early results from the UNITY-NHL phase II clinical trial show umbralisib to be highly active against relapsed/refractory marginal zone lymphoma, with a 55% partial or complete response rate and 71% progression-free survival at 12 months.
Researchers have engineered HBV-specific T cells to treat Hepatocellular carcinoma, a commonly occurring liver cancer. The treatment was individualised and showed promise in reducing tumour size in patients with HBV-related liver cancer.
The Endocrine Society's Clinical Practice Guideline recommends treating postmenopausal women with pharmacological therapies to reduce fracture risk, outweighing the risks of rare side effects. Guidelines also provide recommendations for monitoring and reassessing fracture risk after initial treatment.
A study presented at ENDO 2019 found that oxytocin weakens the connection between brain areas involved in food processing, potentially targeting overeating and obesity. Oxytocin modulates the brain's reward system during responses to highly palatable foods.
Researchers identified a new protocol to prioritize HCV treatment in US prisons, considering factors like liver health state, sentence length, and injection drug use. The approach aims to reduce hepatitis C-caused mortality and infections, both in prisons and the community.
The new in vitro method allows scientists to easily screen different compositions of the carrier liquid and concentration of particulates, reducing mouth residue and making swallowing easier. This innovative test is expected to help develop novel medicines that improve the lives of people with difficult swallowing capabilities.
A new device, paired with a customized video game, helps retrain stroke survivors' arm muscles into moving more normally. Most participants experienced increased arm mobility and reduced arm stiffness, retaining function after finishing the training.
The European Centre for Disease Prevention and Control reports that 275,000 new TB diagnoses were made in 2017, with an estimated 77,000 cases being difficult to treat. New WHO recommendations aim to improve treatment for drug-resistant TB with safer and more effective drugs.
A recent study published in Neuropsychopharmacology found that deep brain stimulation provided significant reduction in depression severity and improved quality of life for patients with treatment-resistant depression. The therapy showed excellent results over one year, with most patients experiencing relief within days.
A new study shows that a simplified catheter ablation procedure can deliver the same outcomes as traditional procedures without the need for complex equipment and staff training. This could lead to reduced waiting lists for atrial fibrillation patients, with 30% more patients receiving treatment within the same budget.
New studies show that catheter ablation is not more effective than drug therapy in preventing strokes and deaths from atrial fibrillation. However, patients who undergo the procedure experience significant improvements in quality of life and symptoms, including reduced hospitalizations and recurrences of the condition.
New research reveals catheter ablation is effective in reducing atrial fibrillation recurrence and improving quality of life for patients, while drug therapy offers no significant benefit. However, the study found that catheter ablation did not reduce death or stroke risk compared to drug therapy.
A €7 million Parkinson's research project, PD-MitoQUANT, will be coordinated by RCSI to deepen understanding of the disease and develop new treatments. The project aims to increase knowledge of how cells in the brain become damaged in Parkinson's, with a focus on mitochondria.
Researchers found that sarcopenia is significantly associated with poor response to cancer treatments, including PD-1 inhibitors. Increasing muscle mass prior to treatment may predict treatment effectiveness and improve long-term outcomes for patients with advanced non-small cell lung cancer.
The University of Oxford and Harrington Discovery Institute have established a global center for rare diseases, combining capabilities to deliver new treatments. The centre aims to address unmet need in rare disease research and will leverage resources to support cutting-edge breakthroughs.
Researchers found therapeutic potential in a rare kidney disease treatment for some mitochondrial disorders, improving mitochondrial metabolism and reducing oxidative stress. However, dosages must be carefully controlled due to narrow therapeutic windows.
A study of over 278,000 births in Finland found an association between steroid treatment and reduced birth weight. Babies exposed to steroids were on average born with lower birthweights, regardless of whether they were premature or full-term.
Researchers found that cognitive behavioral therapy and the drug sertraline effectively reduce depression among people undergoing maintenance hemodialysis. The study, published in Annals of Internal Medicine, suggests that physicians should select the treatment available to patients, considering each comes with its own burdens.
Patients with interstitial lung disease often experience significant treatment burdens, including drug-disease interactions. The study highlights the importance of careful evaluation before treatment initiation to minimize complications.
A clinical trial found sacituzumab govitecan produced a significant treatment response in patients with difficult-to-treat metastatic triple-negative breast cancer, outperforming standard chemotherapy. The drug showed manageable side effects and improved treatment duration.
The American Academy of Sleep Medicine published a clinical practice guideline for the use of positive airway pressure (PAP) therapy to treat obstructive sleep apnea (OSA) in adults. The guideline provides nine recommendations, including the use of PAP therapy as a first-line treatment for OSA in adults with excessive sleepiness.
Researchers conducted an extensive comparison of all drugs used in neuroendocrine tumor treatment, guiding physicians through available options. Combination therapies showed high efficacy, but were often underrepresented in international guidelines.
Recent advances in understanding Parkinson's disease have identified promising developments to slow or stop its progression. Researchers explore new therapeutic targets, targeting non-motor features of the disease, and repurposing drugs for their potential disease-modifying properties.
A team of researchers has identified a potential new therapeutic target for Alzheimer's disease by suppressing the activity of a signaling molecule called eEF2K. This approach may improve protein synthesis capacity and alleviate cognitive and synaptic impairments associated with the disease.
A new drug candidate, givosiran, has shown promising results in treating acute porphyria by preventing attacks and reducing hemin need by up to 83%, according to a recent clinical trial. The study's lead author notes that the treatment can effectively prevent acute attacks in seriously afflicted patients with limited options.
A study published in Restorative Neurology and Neuroscience found that eight weeks of intensive yoga practice significantly decreases the severity of physical and psychological symptoms in patients with active rheumatoid arthritis. The results show marked improvements in inflammatory biomarkers, functional status, and disease activity.
A new assay accurately measures TNF concentrations during adalimumab treatment, revealing that circulating TNF levels increase 50-fold before stabilizing. Lower TNF concentrations after the fourth week are associated with more antibodies against the drug and a lower chance of remission.
New guidelines developed by an international expert panel emphasize the importance of treating neuropsychiatric disorders in HD patients. The guidelines provide general, behavioral, and pharmacologic recommendations for managing symptoms such as agitation, anxiety, apathy, psychosis, and sleep disorders, and highlight the need for regu...
Researchers found that mechanical clot removal can limit disability and improve functional outcomes in stroke patients up to 24 hours after symptom onset. This study suggests that endovascular therapy beyond the normal treatment window can lead to better quality of life for stroke survivors.
Researchers found incomplete and outdated compendia lists of medications and their uses, leading to denied coverage decisions without appeals. Dermatologists face challenges due to the lack of transparency in approval processes.
A new Northwestern University study identifies four factors that can accurately predict the severity and longevity of postpartum depression in new mothers. The study found that early intervention can improve treatment outcomes, and clinicians can tailor care to individual women's needs.
IDIBELL researchers discovered a novel disease affecting brain white matter in children, caused by DEGS1 gene defect. Fingolimod treatment shows promise in correcting ceramide imbalances and promoting oligodendrocyte survival.
Researchers found a significant association between schizophrenia and increased antibody levels against the Epstein-Barr virus. The study suggests that individuals with schizophrenia may be more susceptible to EBV infection due to an abnormal immune response.
Researchers used noncontact imaging to differentiate malignant cells and monitor treatment effectiveness, revealing mechanical properties of tumors that influence disease progression. This technique may lead to personalized therapies and more effective treatments.
Researchers found that aromatase inhibitors suppress estrogen synthesis, but paradoxically increase estrogen levels in the brain, leading to memory and thermal regulation deficits. The study calls for new therapies to prevent breast cancer recurrence while minimizing side effects.
Researchers successfully treated a patient with disfiguring sarcoidosis using a drug approved for rheumatoid arthritis. The treatment showed promising results in reducing skin lesions and halting the activation of the Jak-STAT pathway.
A team of researchers at Washington University in St. Louis has made a significant step towards precision medicine for patients with Long QT Syndrome Type 3, a life-threatening form of irregular heartbeat. By analyzing genetic variation and the nanoscale interaction of a commonly used drug treatment, they determined which patients woul...
A systematic review of clinical studies on prurigo nodularis treatment found neurokinin-1 receptor antagonists to be the most promising emerging therapies. The study highlights the need for higher-powered studies and randomized controlled trials to better evaluate treatment options.
A new transgenic mouse model with fluorescent proteins can quickly reflect therapeutic effects in living mice, allowing for rapid identification of promising treatments. The model was used to test a novel antisense oligonucleotide drug that demonstrated therapeutic activity and corrected aberrant RNA splicing.
Researchers at Kanazawa University have discovered that a baculovirus can completely eliminate liver-stage malaria parasites in mice. The study suggests a new approach to developing non-haemolytic single-dose alternative drugs for P. vivax treatment, potentially reducing the risk of infection and side effects.
Researchers found that checkpoint blockade therapy can sensitize patients to better respond to future use of drugs, even when initial attempts failed. This breakthrough has significant implications for treating relapsing non-Hodgkin lymphoma and Hodgkin lymphoma patients.
The phase-2 JULIET trial found that CAR-T cell therapy achieved a 52% favorable response rate in patients with relapsed or refractory diffuse large B-cell lymphoma, with 40% experiencing complete responses. Sixty-five percent of patients remained relapse-free after one year.
A new study from King's College London found that breathlessness-focused services can significantly reduce patient distress and symptoms of depression. These holistic services, which combine palliative care and self-management strategies, empower patients to take control of their breathlessness and improve their quality of life.